Global health organizations have unveiled an ambitious plan to accelerate the development of vaccines against the rare Bundibugyo strain of Ebola, aiming to have trial-ready candidates available within months as East Africa faces a growing outbreak threat.
The initiative, led by the global vaccine alliance Gavi and the Coalition for Epidemic Preparedness Innovations (CEPI), seeks to overcome a longstanding challenge in epidemic preparedness: the lack of investment in vaccines for diseases that emerge unpredictably and offer limited commercial incentives for manufacturers.
Under the new arrangement, the two organizations are deploying a combined $102 million financing package designed to reduce the financial risks associated with vaccine development and ensure rapid production if a successful candidate emerges.
CEPI will provide up to $62 million in upfront funding to advance promising vaccine candidates into clinical testing. Complementing this effort, Gavi has committed a $40 million guarantee through its First Response Fund, providing manufacturers with assurance that successful vaccines will be purchased and scaled up once they pass human trials.
The strategy combines what experts describe as a "push-pull" financing model. The upfront funding helps developers move quickly through costly research and testing stages, while the purchase guarantee creates a market incentive for companies to invest in manufacturing capacity before an outbreak spirals out of control.
To increase the chances of success, the program is backing three vaccine candidates based on different technologies.
One candidate, developed by IAVI, uses the recombinant vesicular stomatitis virus (rVSV) platform—the same single-dose technology that proved highly effective against the Zaire strain of Ebola. Researchers say this candidate currently has some of the strongest preclinical data among the available options.
A second candidate is being advanced through a partnership involving the University of Oxford and the Serum Institute of India. It uses the ChAdOx1 platform, a non-replicating chimpanzee adenovirus technology that was successfully deployed in the Oxford-AstraZeneca COVID-19 vaccine and can be rapidly adapted for emerging diseases.
The third candidate comes from Moderna and relies on mRNA technology, which instructs human cells to produce specific Ebola proteins and trigger an immune response. The platform is valued for its flexibility and ability to support rapid manufacturing when outbreaks emerge.
The accelerated vaccine effort comes as health authorities monitor an expanding Ebola epidemic affecting parts of the Democratic Republic of the Congo and Uganda. The World Health Organization and the Africa Centres for Disease Control and Prevention have elevated the regional risk level, warning that the outbreak poses a significant public health threat.
Containment efforts have been complicated by the absence of approved vaccines, diagnostics, and treatments specifically targeting the Bundibugyo strain. Response teams are also facing logistical difficulties in areas affected by insecurity and conflict, hampering surveillance and healthcare operations.
If one of the vaccine candidates proves safe and effective, health officials plan to deploy a ring vaccination strategy, in which close contacts of infected individuals and frontline health workers are vaccinated to halt transmission chains and contain the outbreak.
Health experts say the initiative could serve as a model for future epidemic preparedness efforts, demonstrating how innovative financing mechanisms can help close critical gaps in vaccine development before emergencies escalate into global crises.